The fatty liver treatment market size has grown strongly in recent years. It will grow from $23.73 billion in 2024 to $25.12 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to obesity epidemic, sedentary lifestyles, unhealthy diets, limited treatment options, awareness campaigns. 
The fatty liver treatment market size is expected to see strong growth in the next few years. It will grow to $33.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increased disease prevalence, rising healthcare expenditure, growing diabetes and metabolic syndrome, innovation in therapeutics. Major trends in the forecast period include precision medicine approaches, lifestyle modification programs, targeted therapies for Nash, non-invasive monitoring tools, technological advancements.
The rise in alcohol consumption is anticipated to drive the growth of the fatty liver treatment market in the future. Alcohol consumption refers to the intake of beverages that contain alcohol, which is a psychoactive substance that depresses the central nervous system. This consumption can exacerbate fatty liver disease and lead to more serious liver conditions, such as alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For example, in March 2023, the HRB National Drugs Library, an Ireland-based government-funded organization, reported that in 2022, alcohol consumption in Scotland rose to 10.2 liters of pure alcohol per capita among individuals aged 15 and older, marking a 7.6% increase compared to 2021. This trend indicates a worrying rise in alcohol intake despite ongoing public health initiatives aimed at reducing consumption. Consequently, the increase in alcohol consumption is fueling the growth of the fatty liver treatment market.
The high prevalence of diabetes is anticipated to contribute significantly to the growth of the fatty liver treatment market. Diabetes, characterized by a substantial proportion of the population diagnosed at a specific point, is a prominent risk factor for the development and progression of fatty liver disease. Metabolic imbalances in individuals with diabetes often lead to the accumulation of fat in the liver. Data from The British Diabetic Association, published in April 2023, reported that 4.3 million individuals in the UK have diabetes, with more than 2.4 million at high risk of acquiring type 2 diabetes. The prevalence of diabetes is driving the growth of the fatty liver treatment market.
Product innovation is a significant trend gaining traction in the fatty liver treatment market. Leading companies in this sector are focusing on developing innovative products to enhance their market position. For example, in March 2023, Akero Therapeutics, a biotechnology company based in the US, announced positive Phase II results for efruxifermin, which is indicated for the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This product is a unique Fc-FGF21 fusion protein that mimics the biological activity of fibroblast growth factor 21 (FGF21), which plays a role in regulating various metabolic pathways and cellular processes.
Strategic alliances are a pivotal focus for major companies in the fatty liver treatment market to enhance their market positions. These alliances, designed for mutual benefits and market strengthening, come in various forms. In October 2023, Torrent Pharmaceuticals, an India-based pharmaceutical company, formed an agreement with Zydus Lifesciences, another India-based pharmaceutical company. Together, they aimed to co-market a groundbreaking medication for treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This collaboration, focused on making Saroglitazar Mg more widely accessible in India, secured semi-exclusive rights for Torrent Pharmaceuticals to co-market the product as Vorxar.
In March 2023, Ipsen, a France-based biopharmaceutical company, completed the acquisition of Albireo Pharma Inc. for $952 million. This strategic move significantly expanded Ipsen's portfolio of rare diseases, focusing on unique pipeline potential for therapies in rare cholestatic liver diseases in both children and adults. Albireo Pharma Inc., a U.S.-based biotechnology company, specializes in developing bile acid modulators for the treatment of fatty liver disorders.
Major companies operating in the fatty liver treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, GlaxoSmithkline plc, Mitsubishi Chemical Holdings, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Eisai Co. Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, GW Pharmaceuticals Limited, Retrophin Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., AbbKine Scientific Co. Ltd., Daewoong Co. Ltd., Madrigal Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Limited, Genfit, NGM Biopharmaceuticals Inc., Cardax Inc., Conatus Pharmaceuticals Inc., Limerick Biopharma Inc.
North America was the largest region in the fatty liver treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fatty liver treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Fatty liver disease is a condition characterized by the accumulation of fat in the liver, leading to various symptoms and complications. Fatty liver treatment encompasses multiple strategies, interventions, and actions aimed at addressing and managing this condition.
The primary types of fatty liver treatment include anti-rejection drugs or immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, and anti-viral drugs. Anti-rejection drugs, also known as immunosuppressants, belong to a class of medications designed to suppress or weaken the body's immune response. They are indicated for conditions such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and others. These medications are commonly utilized by hospitals, ambulatory surgery centers, and other healthcare facilities.
The fatty liver treatment market research report is one of a series of new reports that provides fatty liver treatment market statistics, including fatty liver treatment industry global market size, regional shares, competitors with a fatty liver treatment market share, detailed fatty liver treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the fatty liver treatment industry. This fatty liver treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The fatty liver treatment market consists of revenues earned by entities by providing medical evaluation, medical diagnosis, healthcare provider consultations, nutritional guidance, medication management, ongoing monitoring, and weight management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The fatty liver treatment market also includes sales of thiazolidinediones, vitamin E, metformin, statins, polyunsaturated fatty acids, angiotensin receptor blockers, and pentoxifylline, which are used in providing fatty liver treatment services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The fatty liver treatment market size is expected to see strong growth in the next few years. It will grow to $33.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increased disease prevalence, rising healthcare expenditure, growing diabetes and metabolic syndrome, innovation in therapeutics. Major trends in the forecast period include precision medicine approaches, lifestyle modification programs, targeted therapies for Nash, non-invasive monitoring tools, technological advancements.
The rise in alcohol consumption is anticipated to drive the growth of the fatty liver treatment market in the future. Alcohol consumption refers to the intake of beverages that contain alcohol, which is a psychoactive substance that depresses the central nervous system. This consumption can exacerbate fatty liver disease and lead to more serious liver conditions, such as alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For example, in March 2023, the HRB National Drugs Library, an Ireland-based government-funded organization, reported that in 2022, alcohol consumption in Scotland rose to 10.2 liters of pure alcohol per capita among individuals aged 15 and older, marking a 7.6% increase compared to 2021. This trend indicates a worrying rise in alcohol intake despite ongoing public health initiatives aimed at reducing consumption. Consequently, the increase in alcohol consumption is fueling the growth of the fatty liver treatment market.
The high prevalence of diabetes is anticipated to contribute significantly to the growth of the fatty liver treatment market. Diabetes, characterized by a substantial proportion of the population diagnosed at a specific point, is a prominent risk factor for the development and progression of fatty liver disease. Metabolic imbalances in individuals with diabetes often lead to the accumulation of fat in the liver. Data from The British Diabetic Association, published in April 2023, reported that 4.3 million individuals in the UK have diabetes, with more than 2.4 million at high risk of acquiring type 2 diabetes. The prevalence of diabetes is driving the growth of the fatty liver treatment market.
Product innovation is a significant trend gaining traction in the fatty liver treatment market. Leading companies in this sector are focusing on developing innovative products to enhance their market position. For example, in March 2023, Akero Therapeutics, a biotechnology company based in the US, announced positive Phase II results for efruxifermin, which is indicated for the treatment of non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This product is a unique Fc-FGF21 fusion protein that mimics the biological activity of fibroblast growth factor 21 (FGF21), which plays a role in regulating various metabolic pathways and cellular processes.
Strategic alliances are a pivotal focus for major companies in the fatty liver treatment market to enhance their market positions. These alliances, designed for mutual benefits and market strengthening, come in various forms. In October 2023, Torrent Pharmaceuticals, an India-based pharmaceutical company, formed an agreement with Zydus Lifesciences, another India-based pharmaceutical company. Together, they aimed to co-market a groundbreaking medication for treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This collaboration, focused on making Saroglitazar Mg more widely accessible in India, secured semi-exclusive rights for Torrent Pharmaceuticals to co-market the product as Vorxar.
In March 2023, Ipsen, a France-based biopharmaceutical company, completed the acquisition of Albireo Pharma Inc. for $952 million. This strategic move significantly expanded Ipsen's portfolio of rare diseases, focusing on unique pipeline potential for therapies in rare cholestatic liver diseases in both children and adults. Albireo Pharma Inc., a U.S.-based biotechnology company, specializes in developing bile acid modulators for the treatment of fatty liver disorders.
Major companies operating in the fatty liver treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, GlaxoSmithkline plc, Mitsubishi Chemical Holdings, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Eisai Co. Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, GW Pharmaceuticals Limited, Retrophin Inc., Alnylam Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., AbbKine Scientific Co. Ltd., Daewoong Co. Ltd., Madrigal Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Limited, Genfit, NGM Biopharmaceuticals Inc., Cardax Inc., Conatus Pharmaceuticals Inc., Limerick Biopharma Inc.
North America was the largest region in the fatty liver treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fatty liver treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Fatty liver disease is a condition characterized by the accumulation of fat in the liver, leading to various symptoms and complications. Fatty liver treatment encompasses multiple strategies, interventions, and actions aimed at addressing and managing this condition.
The primary types of fatty liver treatment include anti-rejection drugs or immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, and anti-viral drugs. Anti-rejection drugs, also known as immunosuppressants, belong to a class of medications designed to suppress or weaken the body's immune response. They are indicated for conditions such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and others. These medications are commonly utilized by hospitals, ambulatory surgery centers, and other healthcare facilities.
The fatty liver treatment market research report is one of a series of new reports that provides fatty liver treatment market statistics, including fatty liver treatment industry global market size, regional shares, competitors with a fatty liver treatment market share, detailed fatty liver treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the fatty liver treatment industry. This fatty liver treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The fatty liver treatment market consists of revenues earned by entities by providing medical evaluation, medical diagnosis, healthcare provider consultations, nutritional guidance, medication management, ongoing monitoring, and weight management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The fatty liver treatment market also includes sales of thiazolidinediones, vitamin E, metformin, statins, polyunsaturated fatty acids, angiotensin receptor blockers, and pentoxifylline, which are used in providing fatty liver treatment services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Fatty Liver Treatment Market Characteristics3. Fatty Liver Treatment Market Trends and Strategies4. Fatty Liver Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Fatty Liver Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Fatty Liver Treatment Market34. Recent Developments in the Fatty Liver Treatment Market
5. Global Fatty Liver Treatment Growth Analysis and Strategic Analysis Framework
6. Fatty Liver Treatment Market Segmentation
7. Fatty Liver Treatment Market Regional and Country Analysis
8. Asia-Pacific Fatty Liver Treatment Market
9. China Fatty Liver Treatment Market
10. India Fatty Liver Treatment Market
11. Japan Fatty Liver Treatment Market
12. Australia Fatty Liver Treatment Market
13. Indonesia Fatty Liver Treatment Market
14. South Korea Fatty Liver Treatment Market
15. Western Europe Fatty Liver Treatment Market
16. UK Fatty Liver Treatment Market
17. Germany Fatty Liver Treatment Market
18. France Fatty Liver Treatment Market
19. Italy Fatty Liver Treatment Market
20. Spain Fatty Liver Treatment Market
21. Eastern Europe Fatty Liver Treatment Market
22. Russia Fatty Liver Treatment Market
23. North America Fatty Liver Treatment Market
24. USA Fatty Liver Treatment Market
25. Canada Fatty Liver Treatment Market
26. South America Fatty Liver Treatment Market
27. Brazil Fatty Liver Treatment Market
28. Middle East Fatty Liver Treatment Market
29. Africa Fatty Liver Treatment Market
30. Fatty Liver Treatment Market Competitive Landscape and Company Profiles
31. Fatty Liver Treatment Market Other Major and Innovative Companies
35. Fatty Liver Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Fatty Liver Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on fatty liver treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for fatty liver treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fatty liver treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Anti-Rejection Drugs or Immunosuppressants; Chemotherapy Drugs; Targeted Therapy; Vaccines; Anti-Viral Drugs2) By Disease Type: Hepatitis; Liver Cancer; Non-Alcoholic Fatty Liver Disease; Other Diseases
3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
Subsegments:
1) By Anti-Rejection Drugs or Immunosuppressants: Corticosteroids; Calcineurin Inhibitors; mTOR Inhibitors2) By Chemotherapy Drugs: Conventional Chemotherapy Agents; Novel Chemotherapeutics Under Investigation
3) By Targeted Therapy: Small Molecule Inhibitors; Monoclonal Antibodies
4) By Vaccines: Therapeutic Vaccines; Preventive Vaccines
5) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs); Nucleos(t)ide Analogs
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Hoffmann La Roche Ltd.; AstraZeneca plc; Merck & Co. Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Hoffmann La Roche Ltd.
- AstraZeneca plc
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- The Bristol-Myers Squibb Company
- GlaxoSmithkline plc
- Mitsubishi Chemical Holdings
- Takeda Pharmaceutical Company Limited
- Gilead Sciences Inc.
- Novo Nordisk A/S
- Eisai Co. Ltd.
- Zydus Lifesciences Limited
- Glenmark Pharmaceuticals Limited
- GW Pharmaceuticals Limited
- Retrophin Inc.
- Alnylam Pharmaceuticals Inc.
- Intercept Pharmaceuticals Inc.
- AbbKine Scientific Co. Ltd.
- Daewoong Co. Ltd.
- Madrigal Pharmaceuticals Inc.
- Orchid Chemicals & Pharmaceuticals Limited
- Genfit
- NGM Biopharmaceuticals Inc.
- Cardax Inc.
- Conatus Pharmaceuticals Inc.
- Limerick Biopharma Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 25.12 Billion |
| Forecasted Market Value ( USD | $ 33.07 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
